{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Melanoma",
      "anti-PD-1",
      "cancer"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33125301",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "01",
    "Day": "25"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "11",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1080/07357907.2020.1844893"
    ],
    "Journal": {
      "ISSN": "1532-4192",
      "JournalIssue": {
        "Volume": "39",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Cancer investigation",
      "ISOAbbreviation": "Cancer Invest"
    },
    "ArticleTitle": "Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.",
    "Pagination": {
      "StartPage": "9",
      "EndPage": "14",
      "MedlinePgn": "9-14"
    },
    "Abstract": {
      "AbstractText": [
        "The outbreak of COVID-19 pandemia is a major health worldwide concern. Patients with cancer might have a worse outcome, because of the immunosuppression determined by the tumor itself and anti-cancer treatments, including chemotherapy and radiotherapy. The impact and course of viral infection in patients receiving immunotherapy remains unknown. We report the case of a patient with metastatic melanoma, long responder to anti PD-1 blockade who got infected with Sars CoV-2, recovering without sequelae. A critical review of literature was performed. Limited data available in literature support the possibility to continue the immunotherapy in patients with cancer under control."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Pala",
        "ForeName": "Laura",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Conforti",
        "ForeName": "Fabio",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Cocorocchio",
        "ForeName": "Emilia",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Ferrucci",
        "ForeName": "Pierfrancesco",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "De Pas",
        "ForeName": "Martino Tommaso",
        "Initials": "MT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          },
          {
            "Identifier": [],
            "Affiliation": "Research Nurses Team, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Stucchi",
        "ForeName": "Sara",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Oncology and Haematology, University of Milan, Milan, Italy."
          }
        ],
        "LastName": "Repetto",
        "ForeName": "Matteo",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Saponara",
        "ForeName": "Maristella",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy."
          }
        ],
        "LastName": "Queirolo",
        "ForeName": "Paola",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Cancer Invest",
    "NlmUniqueID": "8307154",
    "ISSNLinking": "0735-7907"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal, Humanized"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents, Immunological"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immune Checkpoint Inhibitors"
    },
    {
      "RegistryNumber": "DPT0O3T46P",
      "NameOfSubstance": "pembrolizumab"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Monoclonal, Humanized"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents, Immunological"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Immune Checkpoint Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Melanoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Metastasis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ]
}